Open an Account
search icon
1
NOTIFICATIONS
Best Algo trading app in India
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 This is further to our letter dated 29th July, 2022 intimating about the date of the Board of Directors Meeting to inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and three months ended 30th June, 2022. We wish to inform that pursuant to regulation 30 and other applicable regulations, if any, of the SEBI LODR, 2015 the Company will hold a conference call for analysts and investors on Friday, 5th August, 2022. The details of the said call are attached herewith and also available on Company's website.
01-08-2022
Bigul

Eris Lifesciences Ltd - 540596 - Board Meeting Intimation for Board Meeting Intimation

 Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2022 ,inter alia, to consider and approve Dear Sir/Madam, NOTICE IS HEREBY given that a Meeting of the Board of Directors of Eris Lifesciences Limited ('the Company') is scheduled to be held on 05 August 2022 to, inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended 30 June 2022. Further, as informed by us vide letter dated 27 June 2022, the trading window has been already closed from 01 July 2022 and will remain closed till 48 hours after the declaration of financial results of the Company pursuant to SEBI [Prohibition of Insider Trading] Regulations, 2015 and Policy on 'Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company for the purpose of Board Meeting.
29-07-2022
Bigul

Eris Lifesciences Ltd - 540596 - APPOINTMENT OF MR. SUJESH VASUDEVAN AS AN ADDITIONAL INDEPENDENT DIRECTOR OF THE COMPANY

 Dear Sir/Madam, We wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved the appointment of Mr. Sujesh Vasudevan (DIN : 08240092) as an 'Additional Director (Non-Executive Independent Director)' on the Board of Directors of the Company vide a circular resolution. The appointment shall have effect from July 25, 2022, and shall continue till July 24, 2027, subject to the approval of the Shareholders of the Company. Further, the details pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') read with Para A of Part A of Schedule III of the Listing Regulations and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, along with the brief profile of Mr. Sujesh Vasudevan is annexed herewith
25-07-2022
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Resignation of Director

 INTIMATION OF RESIGNATION OF INDEPENDENT DIRECTOR OF THE COMPANY
20-07-2022
Bigul

Eris Lifesciences Ltd - 540596 - INTIMATION PURSUANT TO REGULATION 30 OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

 Dear Sir/Madam, We would like to inform that the Company has given a corporate guarantee in favour of Eris Therapeutics Limited ('ETL'), a Wholly Owned Subsidiary, for securing the term loan facility that it availed from Citi Bank N.A. Further, in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') read with Para B (11) of Part A to the Schedule III of the Listing Regulations and circular issued by the Securities and Exchange Board of India vide no. CIR/CFD/CMD/4/2015 dated September 9, 2015, details attached herewith may please be taken on record.
19-07-2022
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING
18-07-2022
Bigul

Eris Lifesciences Ltd - 540596 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 CERTIFICATE UNDER REGULATION 74(5) OF SEBI (DEPOSITORIES AND PARTICIPANTS) REGULATIONS, 2018 FOR THE QUARTER ENDED JUNE 2022
11-07-2022
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING
06-07-2022
Bigul

Eris Lifesciences Ltd - 540596 - INTIMATION OF APPROVAL OF RECLASSIFICATION OF PROMOTER(S)/PROMOTER GROUP

 Dear Sir/Madam, With reference to our application seeking re-classification of Mr. Himanshu Jayantbhai Shah, Promoter of the Company along with his 11 Relatives (forming part of Promoter Group) from the ''Promoter'' Category to the ''Public'' Category, we now wish to inform you that the Company has received the approval of National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') for re-classification of the said promoter and promoter group from ''Promoter' Category to ''Public'' Category of shareholders in accordance with Regulation 31A of the SEBI (LODR) Regulations 2015: The approval letters received from NSE and BSE are enclosed. This is for your information and record.
30-06-2022
Bigul

Eris Lifesciences Ltd - 540596 - Closure of Trading Window

 INTIMATION OF CLOSURE OF TRADING WINDOW
27-06-2022
Next Page
Close

Let's Open Free Demat Account